Glycorex Transplantation AB (GTAB B): Interim report January-June 2022
Accelerating sales growth“Glycorex had a strong second quarter of 2022 with solid double-digit growth. Demand grew as the effects of the COVID-19-pandemic continued to subside which, combined with an effective implementation of the company’s G4G strategy, delivered a very good quarter.” – Geert Nygaard, CEO Financial information April – June 2022 · Net sales: SEK 11.2 million (8.0) · Operating income: SEK -1.7 million (-2.2) · Net income for the period: SEK -1.7 million (-2.3) · Earnings per share: SEK -0.02 (-0.03) Events in the second quarter · Distributor